Patients had fewer bleeds after treatment with Beqvez compared to standard treatment, but questions remain about which ...

The FDA expects to issue a decision in the first quarter of 2025, and if the agency grants approval, it will expand the biomarker-eligible population for the drug.

In a draft guidance, the institute did not recommend Orserdu, but is collecting additional data and public comments on this preliminary decision.

The clinical trial testing ATA-200 to treat a type of LGMD caused by mutations in the SGCG gene has already been cleared in Italy and France.

NEW YORK – VieCure said on Monday that it has raised $45 million, which it will put toward advancing its next-generation clinical decision support solution and expanding the scale of its commercial ...

The collaboration will focus on researching the prevalence of ALT in cancer and its genetic drivers to develop new treatments.

The firm is focusing on hematology, immunology, and oncology, liver, and lung conditions, while seeking partnerships beyond these core areas.

The companies will initially develop an AI-based test to select patients with CDH17-expressing gastrointestinal cancers for Arbele's Phase I drug trial.

Researchers are planning a clinical trial after four metastatic FGFR2 fusion-positive pancreatic cancer patients responded to ...

In a report, a working group cautioned that the program must lessen its reliance on congressional appropriations or risk ...

Researchers reported at the ESMO Congress that 78 percent of patients responded to front-line treatment with Lumakras, ...